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Introduction
Genetic analysis for autoinflammatory disease may reveal
sequence changes of uncertain clinical significance. We
describe investigation of a 26 year old with unexplained
inflammatory symptoms with a novel intronic change in
TNFRSF1A (intron 4 c.472+88 C>A) by examining
reverse-phase protein microarray. In addition we describe
clinical symptoms and response to anakinra and
etanercept.
Objectives
To assess whether this subject with intronic change had
laboratory and clinical features which would confirm a
diagnosis of TRAPS.
Methods
Clinical history was documented along with clinical
response to prednisolone, anakinra and etanercept. Intra-
cellular signaling pathways that govern inflammation asso-
ciated with TNFRSF1A signaling pathways were examined
in peripheral blood mononuclear cells (PBMC) using
reverse-phase protein microarray. Profiles were compared
between the subject with intronic change, C33Y TRAPS
subjects and matched healthy control.
Results
Clinical history confirmed some clinical features of TRAPS
with fevers up to 40 degrees C from childhood and
frequent episodes of myalgia, vomiting and abdominal
pain lasting up to 4 weeks. On many occasions, however,
symptoms were associated with normal CRP and SAA.
Symptoms responded to oral prednisolone but no benefit
occurred with anakinra. Subsequent treatment with
etanercept resulted in less frequent and severe attacks.
Reverse phase protein microarray technology of signal-
ing pathways has previously demonstrated that PBMC
from patients with C33Y TRAPS show subtle upregulation
of NF-kB, p38, MEK/ERK and JNK MAP kinase pathways,
Phosphinositide 3 kinase, STAT3, JAK2/c-Src, GSK-3beta
and transcription factors including ATF, Elk and Jun. The
microarray from subject with intronic change did not
show any significant variations compared to healthy con-
trol and did not resemble a C33Y TRAPS profile. However
some proteins such as pERK1/2, pP38 and TRAF6 were
downregulated in subject intron compared to control.
Conclusion
This subject with intronic change lacks some typical clini-
cal features of TRAPS such as lack of acute phase response
and responsiveness to anakinra. In addition protein array
profile did not resemble that of C33Y TRAPS patient. This
subject does however have a chronic recurrent febrile ill-
ness associated with TNFRSF1A intronic change and
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